article thumbnail

Deucravacitinib Demonstrates Sustained Efficacy and Safety in 4-Year Psoriasis Trial

Dermatology Times

Bristol Myers Squibb announced 70% of patients maintained significant improvement after 4 years with no new safety concerns.

Safety 74
article thumbnail

New Five-year Study Backs Deucravacitinib’s Safety and Efficacy in PsO

The Dermatology Digest

Deucravacitinib (Sotyktu, Bristol Myers Squibb) showed consistent safety and efficacy in patients with in moderate-to-severe plaque psoriasis for up to five years, new research shows. Moreover, the safety profile of deucravacitinib remained consistent through five years with no new safety signals identified.

Safety 36
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

20+ Years in the Skincare Industry: Advice From an Esthetician

Kim Gallo Esthetics

The rise of transparency in ingredients, cruelty-free products, and sustainable packaging reflect not just our wish to appear youthful but our desire to live conscientiously. Recognizing skincare as a journey, not a race, is crucial for maintaining sustainable and lifelong skin health.

Skincare 296
article thumbnail

Phase 3 Data Confirms Long-Term Efficacy, Sustained Safety of Oral Remibrutinib for CSU

Dermatology Times

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

article thumbnail

Dupilumab (Dupixent, Sanofi & Regeneron) Shows More Promise in BP

The Dermatology Digest

The safety and efficacy of dupilumab in BP are currently under clinical investigation and have not been evaluated by any regulatory authority. Sustained disease remission was defined as complete clinical remission with completion of OCS taper by week 16 without relapse and no rescue therapy use during the 36-week treatment period.

article thumbnail

U.S FDA Approves Mirdametinib (Gomekli, SpringWorks) for Adult and Pediatric Patients With NF1-PN

The Dermatology Digest

It was very encouraging in the ReNeu trial to see that Gomekli provided deep and durable responses, with a manageable safety profile that enabled patients to stay on therapy. Gomekli demonstrated a manageable safety and tolerability profile.

article thumbnail

New Phase 3 Data on Long-Term Efficacy of Upadacitinib in Atopic Dermatitis Presented at EADV

Dermatology Times

The data presents compelling evidence for the sustained efficacy and safety of the oral JAK1 inhibitor in the treatment of moderate to severe atopic dermatitis over an extended 140-week period.